Q32 Bio Inc. announced the appointment of Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer on June 25, 2025, succeeding Jason Campagna, M.D., Ph.D., who is departing the company. Dr. Sipos is an immunologist with over 25 years of clinical development and medical affairs leadership experience in Immunology and Inflammation (I&I) drug development.
Dr. Sipos's expertise is expected to be valuable as Q32 Bio advances bempikibart in the ongoing Part B and open-label extension portions of the SIGNAL-AA Phase 2a clinical trial for alopecia areata. Prior to joining Q32 Bio, she served as President and Chief Medical Officer at PRAXICO Inc. and was Head of Immunology, Late-Stage Clinical Development at Biogen, Inc.
This leadership change aims to strengthen the team as the company approaches topline results from the SIGNAL-AA Part B portion in the first half of next year. The appointment underscores Q32 Bio's commitment to its core bempikibart program and its strategic importance.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.